Aurobindo Pharma
BSE: 524804 | NSE: AUROPHARMA | ISIN: INE406A01029 | Pharmaceuticals
Nine Months of Aurobindo Pharma |
------------------- in Rs. Cr. ------------------- |
 |
|
|
Dec '04 |
Dec '05 |
Dec '06 |
Dec '07 |
Dec '08 |
|
| Sales Turnover |
873.57 |
1,009.16 |
1,446.96 |
1,602.33 |
1,948.69 |
| Other Income |
9.04 |
19.15 |
70.14 |
109.20 |
66.75 |
| Total Income |
882.61 |
1,028.31 |
1,517.10 |
1,711.53 |
2,015.44 |
| Total Expenses |
777.07 |
906.43 |
1,233.52 |
1,385.71 |
1,848.49 |
| Operating Profit |
96.50 |
102.73 |
213.44 |
216.62 |
100.20 |
| Profit On Sale Of Assets |
-- |
-- |
-- |
-- |
-- |
| Profit On Sale Of Investments |
-- |
-- |
-- |
-- |
-- |
| Gain/Loss On Foreign Exchange |
-- |
-- |
-- |
-- |
-- |
| VRS Adjustment |
-- |
-- |
-- |
-- |
-- |
| Other Extraordinary Income/Expenses |
-- |
-- |
-- |
-- |
-- |
| Total Extraordinary Income/Expenses |
-- |
-- |
-- |
-- |
-- |
| Tax On Extraordinary Items |
-- |
-- |
-- |
-- |
-- |
| Net Extra Ordinary Income/Expenses |
-- |
-- |
-- |
-- |
-- |
| Gross Profit |
105.54 |
121.88 |
283.58 |
325.82 |
166.95 |
| Interest |
27.96 |
43.86 |
58.00 |
11.73 |
34.81 |
| PBDT |
77.58 |
78.02 |
225.58 |
314.09 |
132.14 |
| Depreciation |
35.80 |
37.78 |
45.56 |
55.27 |
61.08 |
| Depreciation On Revaluation Of Assets |
-- |
-- |
-- |
-- |
-- |
| PBT |
41.78 |
40.24 |
180.02 |
258.82 |
71.06 |
| Tax |
10.43 |
8.39 |
29.97 |
44.12 |
32.30 |
| Net Profit |
31.35 |
31.85 |
150.05 |
214.70 |
38.76 |
| Prior Years Income/Expenses |
0.18 |
-0.01 |
0.92 |
-- |
3.33 |
| Depreciation for Previous Years Written Back/ Provided |
-- |
-- |
-- |
-- |
-- |
| Dividend |
-- |
-- |
-- |
-- |
-- |
| Dividend Tax |
-- |
-- |
-- |
-- |
-- |
| Dividend (%) |
-- |
-- |
-- |
-- |
-- |
| Earnings Per Share |
6.17 |
5.98 |
28.13 |
39.93 |
7.21 |
| Book Value |
-- |
-- |
-- |
-- |
-- |
| Equity |
25.39 |
26.64 |
26.67 |
26.88 |
26.88 |
| Reserves |
-- |
-- |
-- |
-- |
-- |
| Face Value |
5.00 |
5.00 |
5.00 |
5.00 |
5.00 |
|
|
|
|
| Source : Religare Technova |
| Explore Aurobindo Pharm connections |
|
